Loxapine — Membership Pricing

Other medications in Mental Health

• Lumateperone
• Lurasidone
• Maprotiline
• Methylphenidate
• Mirtazapine
• Molindone
• Naltrexone
• Nefazodone

About Loxapine

Loxapine is an antipsychotic medication primarily used to manage symptoms of schizophrenia and acute agitation associated with certain mental health conditions. Understanding your treatment options and associated costs is crucial. TheDrugClub is dedicated to helping members access their necessary prescriptions, including loxapine, often at significantly reduced prices, making managing your health more affordable.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Loxapine is approved for (FDA label)

Loxapine capsules are indicated for the treatment of schizophrenia. The efficacy of loxapine in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized acutely ill schizophrenic patients as subjects.

Source: Read the full FDA label on DailyMed. Label effective date: September 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Loxapine (FDA label)

WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Loxapine is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS ).

Source: FDA prescribing information (DailyMed). Set ID: ce8c5a31-7600-4525-a0c7-b3adc9ec2977. SPL document ID: 5a9a2335-6a8c-9b0d-e063-6294a90ae248. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Loxapine (FDA label)

CNS Effects: Manifestations of adverse effects on the central nervous system, other than extrapyramidal effects, have been seen infrequently. Drowsiness, usually mild, may occur at the beginning of therapy or when dosage is increased. It usually subsides with continued loxapine therapy. The incidence of sedation has been less than that of certain aliphatic phenothiazines and slightly more than the piperazine phenothiazines. Dizziness, faintness, staggering gait, shuffling gait, muscle twitching, weakness, insomnia, agitation, tension, seizures, akinesia, slurred speech, numbness, and confusional states have been reported. Neuroleptic malignant syndrome (NMS) has been reported (see WARNINGS ). Extrapyramidal Symptoms - Neuromuscular (extrapyramidal) reactions during the administration of loxapine have been reported frequently, often during the first few days of treatment.

Source: FDA prescribing information (DailyMed). Set ID: ce8c5a31-7600-4525-a0c7-b3adc9ec2977. SPL document ID: 5a9a2335-6a8c-9b0d-e063-6294a90ae248. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Loxapine (FDA label)

Loxapine is contraindicated in comatose or severe drug-induced depressed states (alcohol, barbiturates, narcotics, etc.). Loxapine is contraindicated in individuals with known hypersensitivity to dibenzoxazepines.

Source: FDA prescribing information (DailyMed). Set ID: ce8c5a31-7600-4525-a0c7-b3adc9ec2977. SPL document ID: 5a9a2335-6a8c-9b0d-e063-6294a90ae248. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Loxapine (FDA label)

There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam. The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required.

Source: FDA prescribing information (DailyMed). Set ID: ce8c5a31-7600-4525-a0c7-b3adc9ec2977. SPL document ID: 5a9a2335-6a8c-9b0d-e063-6294a90ae248. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.